0

NOW ENROLLING: Phase 3 SURPASS-IPF for people with idiopathic pulmonary fibrosis. Click to learn more about our clinical trial.

Skip to Content
Celea Therapeutics
Deupirfenidone
Patients & Physicians
About Us
Careers
News
Contact Us
Celea Therapeutics
Deupirfenidone
Patients & Physicians
About Us
Careers
News
Contact Us
Deupirfenidone
Patients & Physicians
About Us
Careers
News
Contact Us

Ongoing Burden of Idiopathic Pulmonary Fibrosis (IPF) in the Era of Antifibrotics. American College of Chest Physicians Annual Meeting (CHEST). 2024. Graham CS, et al. [Poster]

Publication
Oct 8
Written by Christine Mackenzie
Christine Mackenzie
Previous
Previous

Comparing Experiences at Interstitial Lung Disease (ILD) Centers and Community Pulmonology Practices (CPP)... CHEST Annual Meeting. 2024. Graham CS. [Oral Presentation]

Next
Next

Bayesian Approach for ELEVATE IPF: Randomized, Double-blind, Placebo-controlled Trial... CHEST Annual Meeting. 2024. Zhang Y, et al. [Oral Presentation]

Celea Therapeutics

6 Tide Street, Suite 400
Boston, MA 02210


info@celeatx.com

DEUPIRFENIDONE
PATIENTS & PHYSICIANS
ABOUT US
CAREERS
NEWS & PUBLICATIONS
CONTACT

© 2026 Celea Therapeutics, Inc. All rights reserved. Expanded Access Policy

The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether deupirfenidone is safe and effective. No regulatory agency has made any such determination that deupirfenidone is safe or effective for use by the general public for any indication.